Specialty Pharma Journal Specialty, Precision & Technology
CALGARY, May 8, 2017 /PRNewswire/ – Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) announced today that the United States Food and Drug Administration (FDA) has granted Fast Track designation for REOLYSIN®, the Company’s proprietary immuno-oncology viral agent, for the treatment of metastatic breast cancer. “Fast Track designation represents …
Tag Archives: reolysin
May, 2017
April, 2015
-
17 April
Oncolytics’ Reolysin Receives Orphan Drug Designation for Malignant Glioma
US health regulators granted orphan drug designation to Calgary-based Oncolytics Biotech’s lead brain tumor candidate. The company announced that the US Food and Drug Administration (FDA) granted orphan status to its Reolysin for treatment of malignant glioma. Oncolytics said that it had applied for orphan designation for pediatric high grade …
March, 2015
-
3 March
Oncolytics’ Reolysin Receives Orphan Drug Designations from the FDA
Oncolytics Biotech Inc.’s lead product candidate Reolysin was granted orphan drug designation for two types of cancer this week. The company announced Monday that the US Food and Drug Administration (FDA) granted the drug orphan drug designation for Reolysin for the treatment of cancer of the fallopian tube. On Tuesday, …
February, 2015
-
17 February
FDA Grants Oncolytics’ Pancreatic Cancer Drug Orphan Drug Designation
Today, Oncolytics Biotech Inc. announced that its lead pancreatic cancer drug was granted orphan drug designation by US health regulators. The company said that its lead product candidate, Reolysin, was granted orphan drug status by the US Food and Drug Administration (FDA) for the treatment of pancreatic cancer. The agency provides …